Ann: Trading Halt, page-12

I know I know =), a strategic acquisition requiring a gargantuan cap raise with a target price of 0.05 to support the acquisition =). I'll stop here - I'm being too trollish and people might think im serious by accident. Sounds a lot like "We are getting more than one new clinic in partnership with someone else - cause if it was just one new one we wouldn't have to halt trading".

To be honest I am grateful for any release from them at the moment to soothe the intense pressure building in my throbbing bull.

Anyway I don't want to be too low effort here - so if anyone has any thoughts on:

1. How much they feel Openly - Emyrias smartphone observations monitoring platform - may be able to be used commercially in future? It is being used for EDICT (https://edict.org.au/about-project/meet-the-team/) and you can read more about EDICT here: https://www.brucerobinson.com.au/wp-content/uploads/2021/06/EDICT-Program.pdf. If they can gather a large amount of data and use it to make a more widely integrable vital signs monitoring it could be very lucrative if used by a service like HealthDirect or to flag patients who may need to attend hospital rather than book an appointment with a GP on a playform like HealthEngine.

2. Lets take a look at the evidence for CBD in IBS so that we can make our best guesses about how EMD-004 might go in future when looking at RX-5 for IBS.

Ultimately it looks like any good quality evidence is lacking - so emyria has a gap to fill to find out. Very interesting 2 case reports of refractory symptoms responding - https://www.scielo.br/j/jcol/a/HFWvsKJhpPdRzkHKhPjqqdM/?format=pdf&lang=en but thats far from good evidence. This very small study using CBD gummies (50mg individually capped at 300mg/day) did not have a significant finding https://library.wur.nl/WebQuery/wurpubs/fulltext/552895

Do we know what dose of RX-5 is being used in the EMD-004 trial?